3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Colorectal Neoplasms
14
Neoplasm Metastasis
5
Rectal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Stomach Neoplasms
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Pancreatic Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Gastric Adenocarcinoma
1
Digestive System Diseases
1
Cholangiocarcinoma
1
Carcinoma
1
Bile Duct Neoplasms
1
Advanced or Metastatic Solid Tumors
1
Advanced Solid Tumors
1
Adenocarcinoma
1
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
12
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Axitinib
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Erlotinib Hydrochloride
5
Docetaxel
5
Cyclophosphamide
5
Albumin-Bound Paclitaxel
5
Sorafenib
4
Radiation
4
Nivolumab
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Irinotecan
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
pralsetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
trifluridine tipiracil drug combination
×
Clear all
NCT02920476
2022-06-23
UF-STO-LUNG-003
University of Florida
Phase 2
Completed
4 enrolled
8 charts